The Stop TB Partnership currently has three vacancies available.

A 5-year award of CA$85 million will support innovations in TB detection and care through the Stop TB Partnership's TB REACH initiative.

The Stop TB Partnership released a series of briefs on TB key populations recognizing that reaching everyone with services, diagnostics, treatment and care is essential to ending the TB epidemic. The briefs focus on children, miners, mobile populations, urban populations, prisoners, rural populations and people who use drugs.

Linezolid is a critical component of regimens used to treat multidrug-resistant tuberculosis (MDR-TB). The GDF-negotiated price reduction is projected to save up to US$ 30 million over the next three years, helping to further improve equitable access to MDR-TB treatment.

The Zero Draft 2016 Political Declaration released ahead of the United Nations High-Level Meeting on Ending AIDS contains ambitious commitments to put the world on track to end AIDS and TB by 2030.

The deadline for the 2016 Kochon Prize’s call for nominations has been extended until Friday, 29 April.

7 April 2016 -- New York, USA – Over 100 civil society voices from the TB and HIV communities joined together at UN Headquarters in New York yesterday to call for stronger integration of TB and HIV programs if the world is to reach the UN goals to End TB and HIV by 2030.

31 March 2016 – Geneva, Switzerland - The new fixed-dose paediatric formulations are now available for procurement through the Global Drug Facility (GDF): rifampicin 75 mg + isoniazid 50 mg + pyrazinamide 150 mg and rifampicin 75 mg + isoniazid 50. The products dissolve in water, have a fruit flavour, and are simple to administer.

The Stop TB Partnership released the first of a series of publications on the different TB key populations, Key populations brief: Mobile populations.

Stop TB Partnership launches World TB Day webpage and social media campaign.